Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2015 08:30 ET | Source: Aravive, Inc.

Versartis Initiates Phase 2 Trial (VITAL) of Monthly Somavaratan in Adults With Growth Hormone Deficiency

MENLO PARK, Calif., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form...
September 08, 2015 08:30 ET | Source: Aravive, Inc.

Versartis to Present at Upcoming Investor Conferences

MENLO PARK, Calif., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form...
September 08, 2015 08:30 ET | Source: Aravive, Inc.

Versartis Announces Agenda and Event Details for Investor Symposium Featuring Global Opinion Leaders in Pediatric Human Growth Hormone Deficiency (GHD)

MENLO PARK, Calif., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form...
August 11, 2015 08:30 ET | Source: Aravive, Inc.

Versartis to Host Investor Symposium Featuring Global Opinion Leaders in Pediatric Human Growth Hormone Deficiency

MENLO PARK, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form...
August 04, 2015 16:15 ET | Source: Aravive, Inc.

Versartis to Present at the Canaccord Genuity 35th Annual Growth Conference

MENLO PARK, Calif., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form...
August 04, 2015 08:35 ET | Source: Aravive, Inc.

Versartis Abstract Accepted for Late-Breaker Presentation at the 54th Annual Meeting of the European Society for Paediatric Endocrinology

MENLO PARK, Calif., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317) a novel, long-acting form of...
August 04, 2015 08:30 ET | Source: Aravive, Inc.

Versartis Reports Second Quarter 2015 Financial Results

MENLO PARK, Calif., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form...
July 06, 2015 08:30 ET | Source: Aravive, Inc.

Versartis Announces Removal of FDA Partial Clinical Hold and Continuation of VRS-317 Phase 3 Clinical Trial

MENLO PARK, Calif., July 6, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing VRS-317, a novel, long-acting form of recombinant...
May 06, 2015 16:10 ET | Source: Aravive, Inc.

Versartis to Present at the Bank of America Merrill Lynch 2015 Health Care Conference

MENLO PARK, Calif., May 6, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing VRS-317, a novel, long-acting form of recombinant...
May 06, 2015 16:05 ET | Source: Aravive, Inc.

Versartis Provides Update on Clinical Programs and Reports First Quarter 2015 Financial Results

MENLO PARK, Calif., May 6, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing VRS-317, a novel, long-acting form of recombinant...